Ann: Trading Halt, page-14

On November 11th last year the issue of The Passionate Investor (freely available on the net) included coverage of Dimerix, Nanosonics and Opthea. The overview of Opthea included the Wilson HTM's executive summary. Monday should give us some idea of whether this is is likely to eventuate.

Most recently, Wilsons HTM in a comprehensive 30 page report on Opthea initiated coverage with a "buy" recommendation and a 90c price target.
Analyst Shane Storey said in the executive summary, "We initiate coverage on Opthea with a BUY rating and a risked price target of 90c per share. Opthea is developing a new drug to improve the treatment of wet age- related macular degeneration (w-AMD). w-AMD is a blockbuster drug market with $US7.5 billion in annual sales, although a lot of patients are being "left behind" by the standard of care ...Our thesis is that the scarcity of new projects in this area of medicine and the ongoing growth in the underlying market (population doubling next 5 years) will see the value of OPT-302 increase dramatically over the next 2-3 years. The upside is compelling - we assess up to $5.80 per share, fully diluted, on an un-risked basis. OPT-302 is one of the most exciting Phase II programs in global Pharma, in our view"